Failure of combined factor VIII and cyclophosphamide to suppress antibody to factor VIII in hemophilia.
نویسندگان
چکیده
Two patients with hemophilia A and antiquential antibody titers demonstrated no factor VIII antibodies were treated with change in antibody response in either infusions of factor VIII concentrates and patient when compared to previous studintravenous cyclophosphamide in an aties following factor VIII infusion alone. tempt to suppress the antibody response. These results are in contrast to the preFactor VIII levels of 23% and 95% were viously reported suppression of factor VIII achieved immediately postinfusion, and antibody in a nonhemophilic patient using prompt control of bleeding ensued. Sean identical regimen. T HE DEVELOPMENT OF anti-factor VIII antibodies in a hemophilic patient represents a major complication in the control of hemorrhage. Recent surveys of large groups of hemophilic patients indicate the incidence of such antibodies may be as high as 20#{176} . ‘ Various types of immunosuppressive agents including corticosteroids, 6-mercaptopurine, and azathioprine have been used without success in an effort to modify the rise in antibody titer following factor VIII infusion.4 Green recently reported suppression of acquired factor VIII antibody in a nonhemophilic patient with the combined use of a large dose of factor VIII concentrate followed immediately by intravenous cyclophosphamide.5 We undertook to evaluate this regimen in two hemophilic boys, both of whom had had previous sequential inhibitor titers measured following infusion of factor VIII alone.
منابع مشابه
فراوانی هپاتیتB ، هپاتیتC و ارتباط آنها با ایجاد مهار کننده فاکتور VIII در مبتلایان هموفیلی استان همدان- 1383
Abstract: Background: Hemophilia is a x-linked deficiency of factor VIII. The aim of the present study was to determine the frequencies of hepatitis B and C infections, markers of inflammation and liver function tests and also to assess the possible association between factor VIII inhibitor and hepatitis B and C infections in hemophiliacs of Hamedan Province of Iran. Materials and methods: Si...
متن کاملDetection of Factor VIII Inhibitors in Hemophilia A Patients
Background: Factor VIII administration to hemophilia A patients results in an immune response (inhibitor formation) which significantly complicates the therapy. The present study was performed to determine the prevalence of inhibitor development in hemophilia A patients receiving recombinant factor VIII therapy. Materials and Methods: This was an observational descriptive study. Clotting fac...
متن کاملNoncoagulation inhibitory factor VIII antibodies after induction of tolerance to factor VIII in hemophilia A patients.
We recently described tolerance induction with factor VIII/IX, cyclophosphamide, and high-dose intravenous IgG in hemophilia A or B patients with coagulation inhibitory antibodies. Circulating noninhibitory antibodies complexed with factor IX have been demonstrated in tolerant hemophilia B patients. Similar findings are now described in six tolerant hemophilia A patients. Complexes between fact...
متن کاملCoagulation Therapy in Hemophilia A and its Relation to Factor VIII Inhibitor in Northeast of Iran
متن کامل
Post Splenectomy Fatal Pulmonary Embolism in a Patient with Moderate Hemophilia A
Hemophilia A is a bleeding disorder caused by defective production of factor VIII. The main concern associated with the disease is bleeding, especially after trauma and surgeries. Factor VIII replacement therapy is associated with substantial decrease of bleeding events during surgery. However, there have been a number of reports of thromboemblic events in this situ-ation. The present report de...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Blood
دوره 42 6 شماره
صفحات -
تاریخ انتشار 1973